BAYER/NUVELO: BEGINNING A JOINT ADVENTURE
Bayer and Nuvelo have begun enrolling patients for alfimeprase's SONOMA-3 trial.
Bayer and Nuvelo have started patient enrollment in a second phase III clinical
trial of alfimeprase in central venous catheter occlusion. The trial marks the
start of Bayer's involvement in the clinical development of the novel thrombolytic
agent following a much-applauded agreement with Nuvelo. However, trials in other
indications may prove to be of more benefit to Bayer's shareholders.
Pharmaceutical Business Review